Evidence map›Paper›PMID 41052886›Full record

ArticleJournal for immunotherapy of cancer2025

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Bernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, Gwangil Kim, Masoud Tafavvoghi, Oleksandr Petrenko, Robert D Goldin, Claudia A M Fulgenzi, Aria Torkpour, Lorenz Balcar and 31 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Bernhard ScheinerImperial College London Department of Surgery and Cancer, London, UK.
Pasquale LombardiImperial College London Department of Surgery and Cancer, London, UK.
Antonio D'AlessioImperial College London Department of Surgery and Cancer, London, UK.ORCID http://orcid.org/0000-0002-9164-3671
Gwangil KimDepartment of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Masoud TafavvoghiDepartment of Cancer Genetics, Oslo University Hospital, Oslo, Norway.
Oleksandr PetrenkoDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-8586-4910
Robert D GoldinImperial College London Department of Surgery and Cancer, London, UK.
Claudia A M FulgenziImperial College London Department of Surgery and Cancer, London, UK.
Aria TorkpourImperial College London Department of Surgery and Cancer, London, UK.
Lorenz BalcarDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Francesco A MauriImperial College London Department of Surgery and Cancer, London, UK.
Katharina PomejDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Vera HimmelsbachDepartment of Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt, Germany.
Maryam BarschDepartment of Internal Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.
Ciro CelsaGastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy.
Giuseppe CabibboGastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy.
Jaekyung CheonMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
Anja KrallDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Steiermark, Austria.
Florian HuckeInternal Medicine and Gastroenterology (IMuG), Including Centralized Emergency Service (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Kärnten, Austria.
Luca Di TommasoDepartment of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Monica BernasconiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Lorenza RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Adel SamsonLeeds Institute of Medical Research at St James's (LIMR), School of Medicine, Faculty of Medicine and Health, University of Leeds, St James's University Hospita, Leeds, UK.
Bernardo StefaniniDepartment of Medical and Surgical Sciences, Bologna University, 40138 Bologna, Italy.
Behrang MozayaniDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Michael TraunerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Carolin LacknerDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Rudolf StauberDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Steiermark, Austria.
Francesco VasuriPathology Unit, IRCCS - Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Fabio PiscagliaDepartment of Medical and Surgical Sciences, Bologna University, 40138 Bologna, Italy.
Bertram BengschDepartment of Internal Medicine II, Medical Center - University of Freiburg, Freiburg, Germany.
Fabian FinkelmeierDepartment of Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt, Germany.
Markus Peck-RadosavljevicInternal Medicine and Gastroenterology (IMuG), Including Centralized Emergency Service (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Kärnten, Austria.
Lill-Tove Rasmussen BusundDepartment of Clinical Pathology, University Hospital of North Norway, Tromso, Norway.
Teresa MarafiotiDepartment of Histopathology, University College London Hospital, London, UK.
Mohammad RahbariDivision of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Mathias HeikenwalderDivision of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matthias PinterDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-7260-532X
Hong Jae ChonMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea david.pinato@imperial.ac.uk hongjaechon@gmail.com.
Mehrdad Rakaee *Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-9080-0153
David J Pinato *Imperial College London Department of Surgery and Cancer, London, UK david.pinato@imperial.ac.uk hongjaechon@gmail.com.ORCID http://orcid.org/0000-0002-3529-0103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spontaneously immunogenic hepatocellular carcinoma (HCC), identified by a dense immune cell infiltrate (ICI), responds better to immunotherapy, although no validated biomarker exists to identify these cases. We used machine learning (ML) to quantify ICI from standard H&E-stained tissue and evaluated its correlation with characteristics of the tumor microenvironment (TME) and clinical outcome from atezolizumab plus bevacizumab (A+B).We therefore employed a supervised ML algorithm on 102 pretreatment H&E slides collected from patients treated with A+B. We quantified tumor, stroma and immune cell counts/mm

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsMachine LearningAgedFemaleHumansMaleMiddle AgedPrognosisTreatment OutcomeTumor MicroenvironmentAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabBiomarkerHepatocellular CarcinomaImmunotherapyTumor infiltrating lymphocyte - TIL

Identifiers

PMID41052886
PMCPMC12506175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.